The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer
Open accessAbstract
Context We have recently witnessed a rapid increase in the number of effective systemic agents for men with metastatic castration-resistant prostate cancer (CRPC), including novel hormonal therapies (abiraterone acetate and MDV3100), immunotherapies (sipu-leucel-T), chemotherapies (cabazitaxel), and bone microenvironment targeting agents (denosumab, radium 223). Given the increasing complexity of treatment decisions for this disease, major research and clinical priorities are (1) finding biomarkers that enable an understanding of the natural history and complex biology of this heterogeneous malignancy, (2) defining predictive biomarkers that identify men most likely to benefit from a given therapy, and (3) identifying biomarkers of early response or progression to optimize outcomes. Objective In this review, we discuss existing and potential biomarkers in CRPC and how they may currently inform prognosis, aid in treatment selection (predictive value), and relate to survival outcomes (surrogacy). Evidence acquisition PubMed-based literature searches and abstracts through September 2011 provided the basis for this literature review as well as expert opinion. Evidence synthesis We address blood and urine-based biomarkers such as prostate-specific antigen, lactate dehydrogenase, total and bone alkaline phosphatase and other bone turnover markers, hemoglobin, and circulating tumor cells in the context of prognosis, prediction, and patient selection for therapy. Given the inherent problems associated with defining progression-free survival in CRPC, the importance of biomarker development and the needed steps are highlighted. We place the discussion of bio-markers within the context of the design/intent of a trial and mechanism of action of a given systemic therapy. We discuss novel biomarker development and the pathway for surrogate or predictive biomarkers to become credentialed as useful tests that inform therapeutic decisions. Conclusions A greater understanding of biomarkers in CRPC permits a more personalized approach to care that maximizes benefit and minimizes harm and can inform clinical trials tailored to men most likely to derive benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“An example of a predictive biomarker in oncology is overexpression of the HER2 oncogene in breast cancer, which is adversely prognostic and also predicts benefit with trastuzumab [10].”
BackgroundSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“These include the androgen synthesis inhibitor abiraterone acetate (AA) [1], the immunotherapeutic sipuleucel-T [2], and the taxoid cabazitaxel [3].”
BackgroundSelf-citationAllard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 2×
“The measurement of these rare tumor cells in the circulation of patients with cancer has been studied for >140 yr, but only recently has technology advanced to the point of regulatory approval as a readily available prognostic biomarker [40,41].”
BackgroundAttard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533 · cited 1×
“loss in CTCs [48] suggests that individualized biomarker-driven therapy directly against the AR or PI3 kinase pathway may be possible [48].”
Background
Cited by
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationAntonarakis, E. S., Lu, C., Luber, B., Wang, H., Chen, Y., Nakazawa, M., Nadal, R., Paller, C. J., Denmeade, S. R., Carducci, M. A., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1341 · Cited by 618
Self-citationGillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv257 · Cited by 322
Self-citationGoldkorn, A., Ely, B., Quinn, D. I., Tangen, C. M., Fink, L. M., Xu, T., Twardowski, P., Van Veldhuizen, P. J., Agarwal, N., Carducci, M. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7417 · Cited by 321
Junghans, R. P., Ma, Q., Rathore, R., Gomes, E. M., Bais, A. J., Lo, A. S. Y., Abedi, M., Davies, R. A., Cabral, H. J., Al‐Homsi, A. S., et al. (2016) · The Prostate · doi:10.1002/pros.23214 · Cited by 267
Metadata
- Authors
- Armstrong, A. J., Eisenberger, M. A., Halabi, S., Oudard, S., Nanus, D. M., Petrylak, D. P., Sartor, A. O., & Scher, H. I.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 61
- Issue
- 3
- Pages
- 549-559
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2158176392
- Cited by
- 181
- References
- 5
- FWCI
- 16.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2011.11.009
- The paper
- Armstrong, A. J., Eisenberger, M. A., Halabi, S., Oudard, S., Nanus, D. M., Petrylak, D. P., Sartor, A. O., & Scher, H. I. (2012). Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2011.11.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.